| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | FWBI | Common Stock | Award | $0 | +17,660 | +1056% | $0.000000 | 19,332 | 29 Dec 2023 | Direct | F1, F3 |
| transaction | FWBI | Common Stock | Award | $0 | +20,000 | +103% | $0.000000 | 39,332 | 02 Jan 2024 | Direct | F2, F3 |
| Id | Content |
|---|---|
| F1 | On December 29, 2023, the Reporting Person was granted 17,660 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest upon closing of the Issuer's proposed acquisition of ImmunogenX, Inc. |
| F2 | On January 2, 2024, the Reporting Person was granted 20,000 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest quarterly for one year with 25% vesting quarterly beginning April 1, 2024. |
| F3 | Includes unvested RSUs. |